Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 653
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckRobert L. Ferris, Ezra E.W. Cohen, Nabil F. Saba et al.|JAMA Oncology|2018Cited by 111
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint InhibitorsAdam J. Schoenfeld, Kai He, Emma L. Masteller et al.|Cancer Discovery|2024Cited by 108
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancerElena Garralda, Gerald S. Falchook, Ammar Sukari et al.|ESMO Open|2022Cited by 87
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G. Pfister, Joshua Bauml, Robert I. Haddad et al.|Cancer Medicine|2022Cited by 48